Incyte (INCY)

• Market cap: $16.2B
• 1 day: -3.56%
• 5 days: -3.91%
• 1 month: 1.83%
• 3 months: 20.05%
• 6 months: 22.69%
• Year to date: 19.52%
• 1 year: 31.16%
• 5 years: -10.79%
• 10 years: -35.18%
• Sector: Healthcare
• Industry: Biotechnology

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,617

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

89% more call options, than puts

Call options by funds: $36.9M | Put options by funds: $19.6M

75% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 7 (+3) [Q2]

66% more first-time investments, than exits

New positions opened: 98 | Existing positions closed: 59

17% more capital invested

Capital invested by funds: $11.4B [Q1] → $13.4B (+$1.95B) [Q2]

5% more funds holding

Funds holding: 619 [Q1] → 649 (+30) [Q2]

3.95% more ownership

Funds ownership: 97.53% [Q1] → 101.49% (+3.95%) [Q2]

9% more repeat investments, than reductions

Existing positions increased: 258 | Existing positions reduced: 236

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60
• Avg. target: $85
• High target: $107

10 analyst ratings

• positive: 5 50%
• neutral: 4 40%
• negative: 1 10%

B of A Securities Tazeen Ahmad	$104	Buy Maintained	4 Sep 2025
JP Morgan Jessica Fye	$73	Neutral Maintained	22 Aug 2025
Wells Fargo Derek Archila	$89	Overweight Upgraded	6 Aug 2025
Barclays Luke Sergott	$90	Overweight Initiated	1 Aug 2025
BMO Capital Evan Seigerman	$60	Underperform Maintained	30 Jul 2025